Status:
UNKNOWN
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Lead Sponsor:
G.Gennimatas General Hospital
Collaborating Sponsors:
Attikon Hospital
Conditions:
Left Cardiac Catheterization
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-100 years
Phase:
EARLY_PHASE1
Brief Summary
Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful tool in interventional cardiology, in which iodinated contrast media is used. Although the use of iodinated ...
Eligibility Criteria
Inclusion
- Age\>18 years
- Written informed consent
- Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 \[CKD stage G1-G3\]
- Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients
Exclusion
- Active malignancy
- Participation in other intervention study
- Class I or equivalent indication for treatment with a SGLT2 inhibitor
- Pregnancy or willing of pregnancy during the follow up period
- Active urogenital infection
- Diabetes mellitus type 1
- History of diabetic ketoacidosis
- Cardiogenic shock
- eGFR \< 29 ml/min/1.73m2
- Patients with an indication for SGLT2 inhibitor will be included in a prospective registry. Their treatment will be determined by their attending physicians.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
1722 Patients enrolled
Trial Details
Trial ID
NCT04806633
Start Date
April 1 2021
End Date
December 1 2023
Last Update
March 19 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology Department, Athens General Hospital "G. Gennimatas"
Athens, Greece, 11527
2
2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece.
Athens, Greece, 12462